Risk factors and therapeutic targets in pancreatic cancer

被引:42
|
作者
Woermann, Sonja Maria [1 ]
Alguel, Hana [1 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Med Klin 2, Munich, Germany
来源
FRONTIERS IN ONCOLOGY | 2013年 / 3卷
关键词
pancreatic ductal adenocarcinoma; risk factors; hereditary cancer syndromes; therapeutic targets; signal-transduction pathways; immune response; stroma reaction; epigenetic changes;
D O I
10.3389/fonc.2013.00282
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic cancer (PC) is one of the most challenging tumor entities worldwide, characterized as a highly aggressive disease with dismal overall prognosis and an incidence rate equalling mortality rate. Over the last decade, substantial progress has been made to define the morphological changes and key genetic events in pancreatic carcinogenesis. And yet, it is still unclear what factors trigger PC. Some risk factors appear to be associated with sex, age, race/ethnicity, or other rare genetic conditions. Additionally, modifying factors such as smoking, obesity, diabetes, occupational risk factors, etc., increase the potential for acquiring genetic mutations that may result in PC. Another hallmark of PC is its poor response to radio- and chemo-therapy. Current chemotherapeutic regimens could not provide substantial survival benefit with a clear increase in overall survival. Recently, several new approaches to significantly improve the clinical outcome of PC have been described involving downstream signaling cascades desmoplasia and stromal response as well as tumor microenvironment, immune response, vasculature, and angiogenesis. This review summarizes major risk factors for PC and tries to illuminate relevant targets considerable for new therapeutic approaches.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer
    Gayral, Marion
    Jo, Sebastien
    Hanoun, Naima
    Vignolle-Vidoni, Alix
    Lulka, Hubert
    Delpu, Yannick
    Meulle, Aline
    Dufresne, Marlene
    Humeau, Marine
    du Rieu, Mael Chalret
    Bournet, Barbara
    Selves, Janick
    Guimbaud, Rosine
    Carrere, Nicolas
    Buscail, Louis
    Torrisani, Jerome
    Cordelier, Pierre
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (32) : 11199 - 11209
  • [22] FAK and Interacting Proteins as Therapeutic Targets in Pancreatic Cancer
    Ucar, Deniz A.
    Hochwald, Steven N.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2010, 10 (10) : 742 - 746
  • [23] Pancreatic cancer: molecular pathogenesis and new therapeutic targets
    Wong, Han H.
    Lemoine, Nicholas R.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2009, 6 (07) : 412 - 422
  • [24] Lysyl oxidases are poor therapeutic targets in pancreatic cancer
    Shields, Mario A.
    Maguin, Pascal
    Kumar, Priyanka
    Dallas, Sarah L.
    Egeblad, Mikala
    CANCER RESEARCH, 2015, 75
  • [25] Risk factors for pancreatic cancer
    Lowenfels, AB
    Maisonneuve, P
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2005, 95 (04) : 649 - 656
  • [26] Risk factors for pancreatic cancer
    Adanja, B
    Vlajinac, H
    Kokic, Z
    Jarebinski, M
    Pekmezovic, T
    BALKAN CONGRESS OF ONCOLOGY, 1996, : 953 - 957
  • [27] A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence
    Kurahara, Hiroshi
    Maemura, Kosei
    Mataki, Yuko
    Sakoda, Masahiko
    Iino, Satoshi
    Kawasaki, Yota
    Arigami, Takaaki
    Mori, Shinichiro
    Kijima, Yuko
    Ueno, Shinichi
    Shinchi, Hiroyuki
    Natsugoe, Shoji
    PANCREAS, 2018, 47 (06) : 753 - 758
  • [28] Infection and cancer: risk estimation and therapeutic targets
    Kaneda, Atsushi
    Yeoh, Khay Guan
    CANCER SCIENCE, 2021, 112 : 1055 - 1055
  • [29] Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia
    Creeden, Justin F.
    Alganem, Khaled
    Imami, Ali S.
    Henkel, Nicholas D.
    Brunicardi, F. Charles
    Liu, Shi-He
    Shukla, Rammohan
    Tomar, Tushar
    Naji, Faris
    McCullumsmith, Robert E.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 28
  • [30] Hormones and MS: Risk factors, biomarkers, and therapeutic targets
    Bove, Riley
    Gilmore, Wendy
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (01) : 17 - 21